Literature DB >> 16947632

The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient.

Mumtaz Patel1, Alexandra M Clarke, Ian N Bruce, Deborah P M Symmons.   

Abstract

OBJECTIVE: Renal involvement is a major complication of systemic lupus erythematosus (SLE) and is a strong determinant of morbidity and mortality. There have been no previous studies of the epidemiology of lupus nephritis. Our aim was to establish the prevalence and incidence of biopsy-proven lupus nephritis in the northwest of England in 2001 and to examine the influence of age, sex, and ethnicity.
METHODS: Adults (age 18 years and older) with biopsy-proven lupus nephritis were identified from 5 sources: renal biopsy databases, dialysis/transplant databases, nephrologists' patients, clinic lists, and lupus patient groups. The denominator data for the northwest of England were ascertained from the 2001 census.
RESULTS: We identified 208 cases of biopsy-proven lupus nephritis (176 women, 32 men): the overall prevalence was 4.4 per 100,000 population (95% confidence interval [95% CI] 3.8-5.0), 7.1 per 100,000 (95% CI 6.1-8.2) in women, and 1.4 per 100,000 (95% CI 1.0-2.0) in men. The prevalence was significantly higher among women in the ethnic subgroups: 110.3 per 100,000 population (95% CI 55.0-197.3) in Chinese patients, 99.2 per 100,000 (95% CI 55.5-163.6) in Afro-Caribbean, 21.4 per 100,000 (95% CI 12.0-35.2) in Indo-Asian (Asians from the Indian subcontinent), and 5.6 per 100,000 (95% CI 4.7-6.7) in white patients. The overall annual incidence rate was 0.40 per 100,000 population per year (95% CI 0.24-0.63), with a rate of 0.68 (95% CI 0.40-1.10) in women and 0.09 (95% CI 0.01-0.32) in men. Capture-recapture methods did not suggest any additional cases.
CONCLUSION: This first estimate of the prevalence and incidence of biopsy-proven lupus nephritis demonstrates dramatic differences in prevalence according to ethnicity, with an increasing gradient from the white to the Indo-Asian, Afro-Caribbean, and Chinese populations.

Entities:  

Mesh:

Year:  2006        PMID: 16947632     DOI: 10.1002/art.22079

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

1.  The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

Authors:  Nuala A Helsby; Chung-Yee Hui; Michael A Goldthorpe; Janet K Coller; May Ching Soh; Peter J Gow; Janak Z De Zoysa; Malcolm D Tingle
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

2.  Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement.

Authors:  Muir Morton; Sarah Edmonds; Aislinn M Doherty; Ajay Dhaygude; Matthew Helbert; Mike Venning
Journal:  Rheumatol Int       Date:  2011-11-02       Impact factor: 2.631

Review 3.  Lupus Nephritis: A Different Disease in European Patients?

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Kidney Dis (Basel)       Date:  2015-08-28

4.  Prevalence of health conditions and predictors of mortality in oldest old Mexican Americans and non-Hispanic whites.

Authors:  Rafael Samper-Ternent; Yong Fang Kuo; Laura A Ray; Kenneth J Ottenbacher; Kyriakos S Markides; Soham Al Snih
Journal:  J Am Med Dir Assoc       Date:  2010-10-16       Impact factor: 4.669

Review 5.  The global burden of SLE: prevalence, health disparities and socioeconomic impact.

Authors:  Erin E Carter; Susan G Barr; Ann E Clarke
Journal:  Nat Rev Rheumatol       Date:  2016-08-25       Impact factor: 20.543

6.  Epidemiology of systemic lupus erythematosus: capturing the butterfly.

Authors:  S Sam Lim; Cristina Drenkard
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

7.  Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus.

Authors:  A M Bertoli; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2007-08-24       Impact factor: 19.103

8.  Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism is not a risk factor for hypertension in SLE nephritis.

Authors:  Vir S Negi; Panneer Devaraju; Reena Gulati
Journal:  Clin Rheumatol       Date:  2015-05-10       Impact factor: 2.980

Review 9.  Asian leadership in chronic kidney disease.

Authors:  Gavin J Becker
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

10.  Mycophenolate mofetil in the treatment of lupus nephritis.

Authors:  Patrick Fk Yong; David P D'Cruz
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.